BONSITY: The new name for Alvogen’s Teriparatide Injection 620 mcg/2.48 mL; same affordable alternative to FORTEO® (teriparatide injection)
For US Healthcare Professionals Only
BONSITY teriparatide injection logo

The new name for Alvogen’s Teriparatide Injection 620 mcg/2.48 mL

Request a Rep
Woman's hands holding the BONSITY injection pen

Using Bonsity

Built to streamline administration

BONSITY is designed for ease of use for patients and caregivers.

Actor portrayal.

About the BONSITY pen

Once-daily dosing
Single-patient-use prefilled pen
Self-administer any time of day

The BONSITY pen uses a needle that’s significantly smaller than a typical flu shot needle.* Each pen is metered to deliver 20 mcg of teriparatide per dose each day for up to 28 days. The pen contains additional volume to allow troubleshooting of the device 2 times.1

Download User Manual
BONSITY injection pen
*Needles not included. Becton, Dickinson and Company pen needles from 29- to 31-gauge are recommended for use with the BONSITY device.

Administering BONSITY

BONSITY is administered subcutaneously once a day in the thigh or abdomen. BONSITY is not approved for intravenous or intramuscular use.1† Talk to your patients about how they can rotate injection sites.

Refer to the User Manual for complete instructions on the proper use of BONSITY.

†Use of BONSITY for more than 2 years during a patient's lifetime should only be considered if a patient remains at or has returned to having a high risk for fracture.

Storage and handling1

Instruct patients to store BONSITY in the refrigerator at 36°F to 46°F (2°C to 8°C) between uses.


  • Do not store the BONSITY pen with a needle attached.
  • Do not freeze or use if the pen has been frozen.
  • Do not use after the expiration date printed on the delivery device and packaging.

Disposal of pen needles and injection pen

  • Be sure to remove the pen needle before disposing of the pen
  • Dispose of the pen and used needles as instructed by local and state laws and relevant policies

Traveling with BONSITY

Troubleshooting

If the BONSITY pen is not working properly, please review the troubleshooting guide in the manual. For instructions on how to use, refer to the User Manual.

Download transcript

Important information about BONSITY1



  • Medication may be injected on an empty stomach.
  • BONSITY should appear clear and colorless. Do not use if there are particles present, or if it is cloudy or colored.
  • Inject BONSITY immediately upon removing the device from the refrigerator. After each use, safely dispose of the needle, recap the delivery device, and promptly return it to the refrigerator.
  • Inject once daily in the thigh or abdomen.
  • BONSITY may be taken any time of day. Instruct patients to establish a regular schedule for their injection.
  • Instruct patients to not take more than 1 injection in the same day.
  • Too much BONSITY may result in nausea, vomiting, weakness, or dizziness.
  • Instruct patients and caregivers who administer BONSITY that the contents of the delivery device should not be transferred to a syringe.

Access and affordability

Copay as little as $0 for eligible, commercially insured patients.‡

Explore coverage and savings

Proven efficacy and safety

BONSITY builds on more than 20 years of clinical experience.

See the data
‡Individual costs may vary. Program eligibility and restrictions apply.

Questions about BONSITY?

Connect with a representative to help your patients build new bone with BONSITY

Request a representative
Request
a Rep

Important Safety Information

Indications for use

BONSITY is indicated:

  • For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, BONSITY reduces the risk of vertebral and nonvertebral fractures.
  • To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
  • For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.

Contraindications

BONSITY is contraindicated in patients with hypersensitivity to teriparatide or to any of its excipients. Reactions have included angioedema and anaphylaxis.

Warnings and Precautions

Osteosarcoma: An increased incidence of osteosarcoma was observed in male and female rats treated with BONSITY. Osteosarcoma has been reported in patients treated with BONSITY in the post marketing setting. There are limited data assessing the risk of osteosarcoma beyond 2 years of BONSITY use. Avoid use in patients with: open epiphyses; metabolic bone diseases including Paget's disease of the bone; bone metastases or history of skeletal malignancies; prior external beam or implant radiation therapy involving the skeleton; and hereditary disorders predisposing to osteosarcoma.

Hypercalcemia and Cutaneous Calcification: BONSITY may cause hypercalcemia and may exacerbate hypercalcemia. Avoid BONSITY in patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism.

Serious reports of calciphylaxis and worsening of previously stable cutaneous calcification have been reported in patients taking BONSITY. Risk factors include underlying autoimmune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. Discontinue in patients developing calciphylaxis or worsening of previously stable cutaneous calcification.

Risk of Urolithiasis: BONSITY has not been studied in patients with active urolithiasis. If BONSITY-treated patients have pre-existing hypercalciuria or suspected/known active urolithiasis, consider measuring urinary calcium excretion. Consider the risks and benefits in patients with active or recent urolithiasis because of risk of exacerbation.

Orthostatic Hypotension: BONSITY should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur.

Risk of Digoxin Toxicity: Hypercalcemia may predispose patients to digitalis toxicity because BONSITY transiently increases serum calcium.

Adverse reactions

The most common adverse reactions in clinical trials included: arthralgia, pain, and nausea. Other adverse reactions include dizziness and leg cramps.

Use in specific populations

Pregnancy and Lactation

There is no available data on BONSITY use in pregnant women. Consider discontinuing when pregnancy is recognized.

It is not known whether teriparatide is excreted in human milk, affects human milk production, or has effects on the breastfed infant. Breastfeeding is not recommended.

For additional safety information, please see the full Prescribing Information, including Medication Guide, and full User Manual that accompanies the delivery device.

You are encouraged to report negative side effects of prescription drugs to Alvogen at 1-866-770-3024 or the FDA at www.fda.gov/medwatch, or call 1-800-FDA-1088.

Reference:

  1. BONSITY® [prescribing information]. Morristown, NJ: Alvogen, Inc.

Contact

For questions regarding BONSITY, including insurance coverage:

For medical questions or to report adverse events:

Build new bone with
BONSITY teriparatide injection logo
BONSITY® is a registered trademark of Pfenex, Inc.
All other trademarks are the property of their respective owners.
© 2025 Alvogen. All rights reserved.
BON-WWW-2025  06/25